Nomura Asset Management Co. Ltd. Has $6.60 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Nomura Asset Management Co. Ltd. lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 8.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,593 shares of the life sciences company’s stock after acquiring an additional 4,077 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Illumina were worth $6,598,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Zacks Investment Management purchased a new stake in shares of Illumina during the 3rd quarter worth about $2,924,000. Freemont Management S.A. acquired a new position in Illumina in the third quarter worth approximately $1,565,000. Weybosset Research & Management LLC raised its position in Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after acquiring an additional 8,650 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its stake in Illumina by 176.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after acquiring an additional 4,579 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Illumina by 3.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock worth $41,748,000 after purchasing an additional 13,725 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN stock opened at $146.43 on Friday. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a market capitalization of $23.22 billion, a P/E ratio of -14.70 and a beta of 1.11. The stock has a 50 day moving average of $144.02 and a two-hundred day moving average of $127.89. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.33 earnings per share. As a group, equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ILMN. Canaccord Genuity Group lifted their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. UBS Group boosted their price target on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Stephens increased their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Morgan Stanley restated an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price target for the company from $120.00 to $154.00 in a report on Friday, August 16th. Nine research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Illumina presently has an average rating of “Moderate Buy” and an average price target of $165.86.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.